Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 1.00 |
| ▸ | ARG2 | P78540 | 4/20 | 0.59 |
| ▸ | ARG1 | P05089 | 3/20 | 0.59 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.52 |
| ▸ | GRM8 | O00222 | 1/20 | 0.52 |
| ▸ | GRM6 | O15303 | 1/20 | 0.52 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.52 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.52 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.52 |
| ▸ | GRM5 | P41594 | 1/20 | 0.52 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.52 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.52 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.52 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.52 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.52 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL2802757 | 1.00 | GSR (1.00) | GSRARG2ARG1RNPEPCYP1A2 | |
| Lysine SCHEMBL8613373 | 1.00 | GSR (1.00) | GSRARG2ARG1RNPEPCYP1A2 | |
| Lysine SCHEMBL456381 | 1.00 | GSR (1.00) | GSRARG2ARG1RNPEPCYP1A2 | |
| Lysine SCHEMBL3359527 | 1.00 | GSR (1.00) | GSRARG2ARG1RNPEPCYP1A2 | |
| Lysine SCHEMBL1645 | 1.00 | GSR (1.00) | GSRARG2ARG1RNPEPCYP1A2 | |
| Lysine SCHEMBL12867528 | 1.00 | GSR (1.00) | GSRARG2ARG1RNPEPCYP1A2 | |
| Lysine SCHEMBL9439278 | 1.00 | GSR (1.00) | GSRARG2ARG1RNPEPCYP1A2 | |
| Lysine SCHEMBL20362357 | 1.00 | GSR (1.00) | GSRARG2ARG1RNPEPCYP1A2 | |
| Lysine SCHEMBL7343 | 1.00 | GSR (1.00) | GSRARG2ARG1RNPEPCYP1A2 | |
| Lysine SCHEMBL15303774 | 1.00 | GSR (1.00) | GSRARG2ARG1RNPEPCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745570-B2 | PH dependent adhesive peptides | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2010-06-29 | — | — | US | claimed |
| US-7683025-B2 | Synthesis and self-assembly of ABC triblock bola peptide amphiphiles | NORTHWESTERN UNIVERSITY (US) | 2010-03-23 | — | — | US | claimed |
| US-20090105449-A1 | Novel Ph Dependent Adhesive Peptides | UNITED STATES DEPARTMENT OF ENERGY | 2009-04-23 | — | — | US | claimed |
| WO-2006127048-A2 | NOVEL pH DEPENDENT ADHESIVE PEPTIDES | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2006-11-30 | — | — | WO | claimed |
| EP-4365219-A1 | ASPARTIC ACID COMPOSITION, POLYSUCCINIMIDE COMPOSITION, POLYASPARTIC ACID COMPOSITION, AND CROSS-LINKED POLYASPARTIC ACID COMPOSITION | DIC Corporation (JP) | 2024-05-08 | — | — | EP | disclosed |
| US-20230146694-A1 | PEPTIDE IMMUNOGENS TARGETING PITUITARY ADENYLATE CYCLASE-ACTIVATING PEPTIDE (PACAP) AND FORMULATIONS THEREOF FOR PREVENTION AND TREATMENT OF MIGRAINE | VAXXINITY, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230093678-A1 | PEPTIDE IMMUNOGENS TARGETING PCSK9 AND FORMULATIONS THEREOF FOR PREVENTION AND TREATMENT OF PCSK9-MEDIATED DISORDERS | VAXXINITY, INC. | 2023-03-23 | — | — | US | disclosed |
| WO-2023276396-A1 | ASPARTIC ACID COMPOSITION, POLYSUCCINIMIDE COMPOSITION, POLYASPARTIC ACID COMPOSITION, AND CROSS-LINKED POLYASPARTIC ACID COMPOSITION | DIC株式会社 | 2023-01-05 | — | — | WO | disclosed |
| EP-4103582-A1 | PEPTIDE IMMUNOGENS TARGETING ISLET AMYLOID POLYPEPTIDE (IAPP) FOR PREVENTION AND TREATMENT OF DISORDERS RELATED TO AGGREGATED IAPP | United Biomedical Inc. (US) | 2022-12-21 | — | — | EP | disclosed |
| EP-4097146-A1 | PEPTIDE IMMUNOGENS TARGETING PCSK9 AND FORMULATIONS THEREOF FOR PREVENTION AND TREATMENT OF PCSK9-MEDIATED DISORDERS | United Biomedical Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| EP-4093756-A1 | PEPTIDE IMMUNOGENS TARGETING PITUITARY ADENYLATE CYCLASE-ACTIVATING PEPTIDE (PACAP) AND FORMULATIONS THEREOF FOR PREVENTION AND TREATMENT OF MIGRAINE | United Biomedical Inc. (US) | 2022-11-30 | — | — | EP | disclosed |
| EP-2797625-B1 | SYNTHETIC PEPTIDE-BASED MARKER VACCINE AND DIAGNOSTIC SYSTEM FOR EFFECTIVE CONTROL OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME (PRRS) | UNITED BIOMEDICAL INC (US) | 2022-05-11 | — | — | EP | disclosed |
| WO-2009042779-A1 | HETEROMORPHIC LYSINE FEED GRANULES | ARCHER-DANIELS-MIDLAND COMPANY (US) | 2009-04-02 | — | — | WO | disclosed |
| WO-2006127048-A2 | NOVEL pH DEPENDENT ADHESIVE PEPTIDES | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2006-11-30 | — | — | WO | disclosed |
| EP-1656390-A2 | COMPOSITIONS OF LIPOPEPTIDE ANTIBIOTIC DERIVATIVES AND METHODS OF USE THEREOF | MIGENIX INC. (CA) | 2006-05-17 | — | — | EP | disclosed |
| US-20050214748-A1 | Peptide-based diagnostic reagents for SARS | UNITED BIOMEDICAL, INC. | 2005-09-29 | — | — | US | disclosed |
| US-20050153876-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | MIGENIX INC. (CA) | 2005-07-14 | — | — | US | disclosed |
| WO-2005047308-A2 | PEPTIDE-BASED DIAGNOSTIC REAGENTS FOR SARS | UNITED BIOMEDICAL, INC. (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20050100883-A1 | Peptide-based diagnostic reagents for SARS | UNITED BIOMEDICAL, INC. | 2005-05-12 | — | — | US | disclosed |
| WO-2005000878-A2 | COMPOSITIONS OF LIPOPEPTIDE ANTIBIOTIC DERIVATIVES AND METHODS OF USE THEREOF | MIGENIX INC. (CA) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050100883-A1 | Peptide-based diagnostic reagents for SARS | SARS1, ANPEP, FURIN | GSR 2541/4885ARG2 3710/4885ARG1 2961/4885 |
| US-20050153876-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | NRDC, NOD2, NGLY1 | GSR 3380/4885ARG2 2160/4885ARG1 1476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.